Exploration of synthetic lethal interactions as cancer drug targets

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1789-1802

  Kuiken, Hendrik J ^a   Beijersbergen, Roderick L ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

(non)oncogene addiction; chemical genetic; network addiction; RAS; RNAi; screen; shRNA; siRNA; synthetic lethal interaction

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; PACLITAXEL; RAS PROTEIN; TRASTUZUMAB;

DRUG EFFICACY; GENE INTERACTION; GENETIC SCREENING; GENOMICS; HODGKIN DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MUTATION; PRIORITY JOURNAL; REVIEW; RNA ISOLATION; TESTIS CANCER;

ANIMALS; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, RAS; GENETIC TESTING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RNA INTERFERENCE;

EID: 78650204347     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.131     Document Type: Review

References (82)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
2. Chabner BA, Roberts TG Jr: Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5(1), 65-72 (2005).
3. Einhorn LH, Williams SD: The role of cis-platinum in solid-tumor therapy. N. Engl. J. Med. 300(6), 289-291 (1979).
4. Diehl V, Thomas RK, Re D: Part II: Hodgkin's lymphoma diagnosis and treatment. Lancet Oncol. 5(1), 19-26 (2004).
5. Bernards R: It's diagnostics, stupid. Cell 141(1), 5 (2010).
6. Kaelin WG Jr: Choosing anticancer drug targets in the postgenomic era. J. Clin. Invest. 104(11), 1503-1506 (1999).
7. Beachy PA, Karhadkar SS, Berman DM: Tissue repair and stem cell renewal in carcinogenesis: Nature 432(7015), 324-331 (2004).
8. Sawyers C: Targeted cancer therapy. Nature 432(7015), 294-297 (2004)
9. Druker BJ, Tamura S, Buchdunger E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2(5), 561-566 (1996).
10. Tuveson DA, Willis NA, Jacks T et al.: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20(36), 5054-5058 (2001).
11. Cools J, DeAngelo DJ, Gotlib J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13), 1201-1214 (2003).
12. Sordella R, Bell DW, Haber DA, Settleman J: Geftinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687), 1163-1167 (2004).
13. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
14. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 304(5676), 1497-1500 (2004).
15. Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707-712 (1989).
16. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297(5578), 63-64 (2002).
17. Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22(47), 7389-7395 (2003).
18. Berns K, Horlings HM, Hennessy BT et al.: A functional genetic approach identifes the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4), 395-402 (2007).
19. Engelman JA, Zejnullahu K, Mitsudomi T et al.: MET amplifcation leads to geftinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (5827) , 1039-1043 (2007).
20. Engelman JA, Mukohara T, Zejnullahu K et al.: Allelic dilution obscures detection of a biologically signifcant resistance mutation in EGFR-amplifed lung cancer. J. Clin. Invest. 116(10), 2695-2706 (2006).
21. Guo A, Villen J, Kornhauser J et al.: Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl Acad. Sci. USA 105(2), 692-697 (2008).
22. Tonon G: From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. Future Oncol. 4(4), 569-577 (2008).
23. Sharma SV, Gajowniczek P, Way IP et al.: A common signaling cascade may underlie 'addiction' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10(5), 425-435 (2006).
24. Harris MP, Sutjipto S, Wills KN et al.: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 3(2), 121-130 (1996).
25. Brummelkamp TR, Fabius AW, Mullenders J et al.: An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2(4), 202-206 (2006).
26. Solimini NL, Luo J, Elledge SJ: Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130(6), 986-988 (2007).
27. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136(5), 823-837 (2009).
28. Sharma SV, Settleman J: Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21(24), 3214-3231 (2007).
29. Karnoub AE, Weinberg RA: Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9(7), 517-531 (2008).
30. Chin L, Tam A, Pomerantz J et al.: Essential role for oncogenic Ras in tumour maintenance. Nature 400(6743), 468-472 (1999).
31. Felsher DW, Bishop JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4(2), 199-207 (1999).
32. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G: Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3(5), 565-577 (1999).
33. Lucchesi JC: Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics 59(1), 37-44 (1968).
34. Hartman JL 4th, Garvik B, Hartwell L: Principles for the buffering of genetic variation. Science 291(5506), 1001-1004 (2001).
35. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH: Integrating genetic approaches into the discovery of anticancer drugs. Science 278(5340), 1064-1068 (1997).
36. Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5(9), 689-698 (2005).
37. Bryant HE, Schultz N, Thomas HD et al.: Specifc killing of BRCA2-defcient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035), 913-917 (2005).
38. Farmer H, McCabe N, Lord CJ et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005).
39. Mendes-Pereira AM, Martin SA, Brough R et al.: Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1(6-7), 315-322 (2009).
40. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG: PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10(4), 293-301 (2010).
41. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB: Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 8(19), 3112-3119 (2009).
42. Giaever G, Chu AM, Ni L et al.: Functional profling of the Saccharomyces cerevisiae genome. Nature 418(6896), 387-391 (2002).
43. Dixon SJ, Costanzo M, Baryshnikova A, Andrews B, Boone C: Systematic mapping of genetic interaction networks. Annu. Rev. Genet. 43, 601-625 (2009).
44. Dixon SJ, Andrews BJ, Boone C: Exploring the conservation of synthetic lethal genetic interaction networks. Commun. Integr. Biol. 2(2), 78-81 (2009).
45. Byrne AB, Weirauch MT, Wong V et al.: A global ana lysis of genetic interactions in Caenorhabditis elegans. J. Biol. 6(3), 8 (2007).
46. Tischler J, Lehner B, Fraser AG: Evolutionary plasticity of genetic interaction networks. Nat. Genet. 40(4), 390-391 (2008).
47. Napoli C, Lemieux C, Jorgensen R: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in transplant. Cell 2(4), 279-289 (1990).
48. Montgomery MK, Xu S, Fire A: RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 95(26), 15502-15507 (1998). (Pubitemid 29018728)
49. Iorns E, Lord CJ, Turner N, Ashworth A: Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6(7), 556-568 (2007).
50. Mullenders J, Bernards R: Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 28(50), 4409-4420 (2009).
51. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296(5567), 550-553 (2002).
52. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specifc silencing in mammalian cells. Genes Dev. 16(8), 948-958 (2002).
53. Berns K, Hijmans EM, Mullenders J et al.: A large-scale RNAi screen in human cells identifes new components of the p53 pathway. Nature 428(6981), 431-437 (2004).
54. Schlabach MR, Luo J, Solimini NL et al.: Cancer proliferation gene discovery through functional genomics. Science 319(5863), 620-624 (2008).
55. Silva JM, Marran K, Parker JS et al.: Profling essential genes in human mammary cells by multiplex RNAi screening. Science 319 (5863), 617-620 (2008).
56. Rottmann S, Wang Y, Nasoff M, Deveraux QL, Quon KC: A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3p/FBW7 loss of function. Proc. Natl Acad. Sci. USA 102(42), 15195-15200 (2005).
57. Ricci MS, Jin Z, Dews M et al.: Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity Mol. Cell. Biol. 24(19), 8541-8555 (2004).
58. Welcker M, Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8(2), 83-93 (2008).
59. Ngo VN, Davis RE, Lamy L et al.: A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441(7089), 106-110 (2006).
60. Davis RE, Brown KD, Siebenlist U, Staudt LM: Constitutive nuclear factor KB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194(12), 1861-1874 (2001).
61. Shaffer AL, Emre NC, Lamy L et al.: IRF4 addiction in multiple myeloma. Nature 454(7201), 226-231 (2008).
62. Naik S, Dothager RS, Marasa J, Lewis CL, Piwnica-Worms D: Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant p-catenin activation in colon cancer. Clin. Cancer Res. 15(24), 7529-7537 (2009).
63. Bommi-Reddy A, Almeciga I, Sawyer J et al.: Kinase requirements in human cells: III. Altered kinase requirements in VHL-/-cancer cells detected in a pilot synthetic lethal screen. Proc. Natl Acad. Sci. USA 105(43), 16484-16489 (2008).
64. Sarthy AV, Morgan-Lappe SE, Zakula D et al.: Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol. Cancer Ther. 6(1), 269-276 (2007).
65. Luo J, Emanuele MJ, Li D et al.: A genome-wide RNAi screen identifes multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5), 835-848 (2009).
66. Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6(4), 321-330 (2006).
67. Scholl C, Frohling S, Dunn IF et al.: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137(5), 821-834 (2009).
68. Barbie DA, Tamayo P, Boehm JS et al.: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462(7269), 108-112 (2009).
69. Bartz SR, Zhang Z, Burchard J et al.: Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell Biol. 26(24), 9377-9386 (2006).
70. Giroux V, Iovanna J, Dagorn JC: Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J. 20(12), 1982-1991 (2006).
71. Swanton C, Marani M, Pardo O et al.: Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11(6), 498-512 (2007).
72. Azorsa DO, Gonzales IM, Basu GD et al.: Synthetic lethal RNAi screening identifes sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl Med. 7, 43 (2009).
73. Ji D, Deeds SL, Weinstein EJ: A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol. Rep. 18(6), 1499-1505 (2007).
74. Whitehurst AW, Bodemann BO, Cardenas J et al.: Synthetic lethal screen identifcation of chemosensitizer loci in cancer cells. Nature 446(7137), 815-819 (2007).
75. Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP: Identifcation of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell 12(3), 627-637 (2003).
76. Turner NC, Lord CJ, Iorns E et al.: A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27(9), 1368-1377 (2008).
77. Fotheringham S, Epping MT, Stimson L et al.: Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15(1), 57-66 (2009).
78. Huang S, Laoukili J, Epping MT et al.: ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 15(4), 328-340 (2009).
79. Iorns E, Turner NC, Elliott R et al.: Identifcation of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13(2), 91-104 (2008).
80. Dolma S, Lessnick SL, Hahn WC, Stockwell BR: Identifcation of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3(3), 285-296 (2003).
81. Yang WS, Stockwell BR: Synthetic lethal screening identifes compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15(3), 234-245 (2008).
82. Ji Z, Mei FC, Lory PL, Gilbertson SR, Chen Y, Cheng X: Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer. Front. Biosci. 14, 2904-2910 (2009).